| scholarly article | Q13442814 |
| P2093 | author name string | Lars Rydén | |
| Klas Malmberg | |||
| Arne Olsson | |||
| Mark Gutniak | |||
| Inga Thrainsdottir | |||
| P2860 | cites work | The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus | Q28190307 |
| The diabetic heart: metabolic causes for the development of a cardiomyopathy | Q35660152 | ||
| Energy metabolism of the heart: from basic concepts to clinical applications | Q40748839 | ||
| Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use. | Q40925170 | ||
| Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. | Q42435174 | ||
| Left ventricular filling abnormalities in non-insulin-dependent diabetes mellitus and improvement by a short-term glycemic control | Q43450355 | ||
| Abnormal myocardial acoustic properties in diabetic patients and their correlation with the severity of disease | Q43742283 | ||
| The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group | Q43924876 | ||
| Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus | Q45306841 | ||
| Subclinical left ventricular abnormalities in young subjects with long-term type 1 diabetes mellitus detected by digitized M-mode echocardiography | Q48524549 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| type 2 diabetes | Q3025883 | ||
| P304 | page(s) | 40-43 | |
| P577 | publication date | 2004-05-01 | |
| P1433 | published in | Diabetes and Vascular Disease Research | Q5270121 |
| P1476 | title | Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure | |
| P478 | volume | 1 |
| Q36090588 | A meta-analysis of the therapeutic effects of glucagon-like Peptide-1 agonist in heart failure. |
| Q30437335 | A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study) |
| Q38826068 | After the LEADER trial and SUSTAIN-6, how do we explain the cardiovascular benefits of some GLP-1 receptor agonists? |
| Q35991064 | Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications |
| Q43236097 | Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes |
| Q35210037 | Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits |
| Q37604142 | Cardiac dysfunction in type II diabetes: a bittersweet, weighty problem, or both? |
| Q38199984 | Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. |
| Q34171759 | Cardiovascular effects of incretin therapy in diabetes care |
| Q36073461 | Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists |
| Q37992255 | Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents |
| Q39390326 | Concise Review: Challenges in Regenerating the Diabetic Heart: A Comprehensive Review |
| Q37882500 | Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. |
| Q38132470 | Direct cardiovascular effects of glucagon like peptide-1. |
| Q39905736 | Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study |
| Q49716961 | Effect of glucose-lowering therapies on heart failure |
| Q33708984 | Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine |
| Q35227453 | Effects of glucagon-like peptide-1 agents on left ventricular function: systematic review and meta-analysis |
| Q38184929 | Effects of incretin-based therapy in patients with heart failure and myocardial infarction |
| Q37172662 | Elevated plasma GLP-1 levels and enhanced expression of cardiac GLP-1 receptors as markers of left ventricular systolic dysfunction: a cross-sectional study |
| Q37395298 | Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? |
| Q36758585 | Emerging drugs for acute and chronic heart failure: current and future developments |
| Q38065321 | Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes |
| Q27024984 | GLP-1 and cardioprotection: from bench to bedside |
| Q53502910 | GLP-1 receptor agonists and heart failure in diabetes. |
| Q38929410 | Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiac Disorders |
| Q34653078 | Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism. |
| Q41267217 | Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure |
| Q28079849 | Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies |
| Q37825946 | Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. |
| Q80241416 | Glycemic control and treatment patterns in patients with heart failure |
| Q38171215 | Heart failure and loss of metabolic control |
| Q38502148 | Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy |
| Q38524435 | Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes |
| Q38264374 | Implications of incretin-based therapies on cardiovascular disease. |
| Q38260853 | Incretin-related drug therapy in heart failure |
| Q38008596 | Incretins as a novel therapeutic strategy in patients with diabetes and heart failure. |
| Q37082698 | Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering |
| Q36336020 | Investigation of the haemodynamic effects of exenatide in healthy male subjects. |
| Q33664253 | Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs |
| Q39199887 | Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure |
| Q57406244 | Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature |
| Q38998576 | Metabolic support for the heart: complementary therapy for heart failure? |
| Q88437125 | Molecular and clinical roles of incretin-based drugs in patients with heart failure |
| Q37260330 | Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. |
| Q36014423 | Polymer-based delivery of glucagon-like Peptide-1 for the treatment of diabetes |
| Q37113253 | Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). |
| Q36721264 | Sitagliptin Modulates the Electrical and Mechanical Characteristics of Pulmonary Vein and Atrium |
| Q37270524 | Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors |
| Q37782506 | Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus |
| Q36368998 | The cardiovascular effects of GLP-1 receptor agonists |
| Q30365939 | The entero-insular axis: implications for human metabolism. |
| Q36830277 | The impact of diabetes on heart failure: opportunities for intervention |
| Q34901533 | The role of incretins in glucose homeostasis and diabetes treatment |
| Q38836416 | Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit |
| Q40036848 | Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists? |
| Q54948267 | Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards. |
| Q83974899 | Update on diabetic cardiomyopathy: inches forward, miles to go |
| Q28073342 | Update on the treatment of type 2 diabetes mellitus |
Search more.